CV Sciences (CVSI) Net Cash Flow Growth (3y) (2014 - 2026)
CV Sciences (CVSI) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -26.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.87% |
| Mar 31, 2026 | -33.71% |
| Dec 31, 2025 | 54.12% |
| Sep 30, 2025 | -188.61% |
| Jun 30, 2025 | 27.11% |
| Mar 31, 2025 | -30.38% |
| Dec 31, 2024 | -22.27% |
| Sep 30, 2024 | 33.62% |
| Jun 30, 2024 | 59.18% |
| Mar 31, 2024 | -37.03% |
| Dec 31, 2023 | 40.39% |
| Sep 30, 2023 | 71.42% |
| Jun 30, 2023 | 26.78% |
| Mar 31, 2023 | 27.06% |
| Dec 31, 2022 | 51.51% |
| Sep 30, 2022 | 26.34% |
| Jun 30, 2022 | -38.06% |
| Mar 31, 2022 | 14.81% |
| Dec 31, 2021 | -29.03% |
| Sep 30, 2021 | -32.84% |